Our partner is making history with every clinical advancement and aspires to turn hope into cures by unraveling new possibilities for genetic medicine. Almost 40 years ago, their scientific co-founder was the first to demonstrate that adeno-associated virus (AAV) could be cloned for therapeutic purposes. This groundbreaking research propelled the most exciting field in medical research today and inspires their world-leading gene therapy platform that is bringing new therapeutics to market and resulting in new methods for lowering the cost of delivery.

This critical hire led the regulatory strategy team and formulated pre-clinical and clinical regulatory strategies. This position also served as the regulatory lead for product programs and worked closely with a cross-function Global Program Team which ensured regulatory strategy alignment and made regulatory submissions high quality and on time.